Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ADEL K EL-NAGGAR and RENATA FERRAROTTO.
ADEL K EL-NAGGAR
Connection Strength
6.503
RENATA FERRAROTTO
  1. Correction: Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2023 Jul 14; 29(14):2737.
    View in: PubMed
    Score: 0.909
  2. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol. 2023 05 20; 41(15):2843-2851.
    View in: PubMed
    Score: 0.887
  3. Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clin Cancer Res. 2021 02 01; 27(3):852-864.
    View in: PubMed
    Score: 0.755
  4. Intratumoral microbiome of adenoid cystic carcinomas and comparison with other head and neck cancers. Sci Rep. 2024 07 15; 14(1):16300.
    View in: PubMed
    Score: 0.244
  5. First Use of AXL Targeting in Metastatic, Refractory, Adenoid Cystic Carcinoma: A Case Report. JCO Precis Oncol. 2024 Apr; 8:e2300633.
    View in: PubMed
    Score: 0.239
  6. Prognostic value of tumor volume doubling time in lung-metastatic adenoid cystic carcinoma. Oral Oncol. 2024 Apr; 151:106759.
    View in: PubMed
    Score: 0.238
  7. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance. Mod Pathol. 2024 Jan; 37(1):100371.
    View in: PubMed
    Score: 0.232
  8. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res. 2023 08 15; 29(16):3162-3171.
    View in: PubMed
    Score: 0.229
  9. Targeting human EGFR 2 (HER2) in salivary gland carcinoma. Expert Rev Anticancer Ther. 2023 06; 23(6):573-582.
    View in: PubMed
    Score: 0.225
  10. Correction: Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Apr 14; 28(8):1735.
    View in: PubMed
    Score: 0.208
  11. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022 02 01; 128(3):509-518.
    View in: PubMed
    Score: 0.201
  12. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
    View in: PubMed
    Score: 0.197
  13. Whole-Genome Sequencing of Common Salivary Gland Carcinomas: Subtype-Restricted and Shared Genetic Alterations. Clin Cancer Res. 2021 07 15; 27(14):3960-3969.
    View in: PubMed
    Score: 0.196
  14. Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma. Clin Cancer Res. 2020 03 01; 26(5):1175-1184.
    View in: PubMed
    Score: 0.177
  15. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020 Feb; 476(2):295-305.
    View in: PubMed
    Score: 0.173
  16. Ectopic ACTH Production and Cushing's Syndrome in a Patient with Parotid Acinic Cell Carcinoma with High-Grade Transformation: Tumor Context and Clinical Implications. Head Neck Pathol. 2020 Jun; 14(2):562-569.
    View in: PubMed
    Score: 0.173
  17. Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
    View in: PubMed
    Score: 0.143
  18. Analysis and significance of c-MET expression in adenoid cystic carcinoma of the salivary gland. Cancer Biol Ther. 2015; 16(6):834-8.
    View in: PubMed
    Score: 0.129
  19. Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications. Clin Cancer Res. 2014 Dec 15; 20(24):6570-81.
    View in: PubMed
    Score: 0.124
  20. Phase II Trial of Induction Chemotherapy for Advanced Sinonasal Squamous Cell Carcinoma. Clin Cancer Res. 2024 Nov 12.
    View in: PubMed
    Score: 0.062
  21. Comprehensive molecular characterization of adenoid cystic carcinoma reveals tumor suppressors as novel drivers and prognostic biomarkers. J Pathol. 2023 11; 261(3):256-268.
    View in: PubMed
    Score: 0.057
  22. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 2023 03 01; 129(5):714-727.
    View in: PubMed
    Score: 0.055
  23. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study. Cancers (Basel). 2022 Jul 28; 14(15).
    View in: PubMed
    Score: 0.053
  24. Elective neck dissection versus observation in patients with head and neck cutaneous squamous cell carcinoma. Cancer. 2021 12 01; 127(23):4413-4420.
    View in: PubMed
    Score: 0.050
  25. Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience. Int J Part Ther. 2021; 8(1):108-118.
    View in: PubMed
    Score: 0.049
  26. Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life. Int J Part Ther. 2021; 8(1):234-247.
    View in: PubMed
    Score: 0.049
  27. Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
    View in: PubMed
    Score: 0.048
  28. Integrating depth of invasion in T classification improves the prognostic performance of the American Joint Committee on Cancer primary tumor staging system for cutaneous squamous cell carcinoma of the head and neck. Eur J Cancer. 2021 02; 144:169-177.
    View in: PubMed
    Score: 0.048
  29. Inclusion of extranodal extension in the lymph node classification of cutaneous squamous cell carcinoma of the head and neck. Cancer. 2021 04 15; 127(8):1238-1245.
    View in: PubMed
    Score: 0.048
  30. Clinical Implication of Diagnostic and Histopathologic Discrepancies in Sinonasal Malignancies. Laryngoscope. 2021 05; 131(5):E1468-E1475.
    View in: PubMed
    Score: 0.047
  31. Oncogenic Orphan Nuclear Receptor NR4A3 Interacts and Cooperates with MYB in Acinic Cell Carcinoma. Cancers (Basel). 2020 Aug 27; 12(9).
    View in: PubMed
    Score: 0.047
  32. Prognostic factors for local recurrence and survival and impact of local treatments on survival in lacrimal gland carcinoma. Br J Ophthalmol. 2021 06; 105(6):768-774.
    View in: PubMed
    Score: 0.046
  33. Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngol Head Neck Surg. 2020 02 01; 146(2):128-135.
    View in: PubMed
    Score: 0.045
  34. PI3-kinase pathway biomarkers in oral cancer and tumor immune cells. Head Neck. 2019 03; 41(3):615-622.
    View in: PubMed
    Score: 0.041
  35. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 2018 09 15; 124(18):3693-3705.
    View in: PubMed
    Score: 0.041
  36. Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer. Oral Oncol. 2018 04; 79:1-8.
    View in: PubMed
    Score: 0.039
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.